Amino Acid Supplement in Parkinson's Disease (NCT06954662)

Amino Acid Supplement Mechanism in Parkinson's Disease

Overview

This page explores the mechanistic basis for amino acid supplementation in Parkinson's disease (PD), with focus on clinical trial NCT06954662: "A Targeted Amino Acid Supplement for People With Parkinson's Disease." The trial investigates whether specialized amino acid formulations can improve dopaminergic medication efficacy by optimizing large neutral amino acid transporter (LAT1) function at the blood-brain barrier.

Trial Details

Amino Acid Supplement Mechanism in Parkinson's Disease

Overview

This page explores the mechanistic basis for amino acid supplementation in Parkinson's disease (PD), with focus on clinical trial NCT06954662: "A Targeted Amino Acid Supplement for People With Parkinson's Disease." The trial investigates whether specialized amino acid formulations can improve dopaminergic medication efficacy by optimizing large neutral amino acid transporter (LAT1) function at the blood-brain barrier.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06954662 |
| Status | Recruiting |
| Phase | Not Applicable |
| Sponsor | Oncovistan Clinical Corp |
| Intervention | Amino acid supplement vs. whey protein vs. placebo |
| Primary Outcome | Levodopa bioavailability and motor function |
| Enrollment | Not specified |
| Study Design | Randomized, controlled trial |

Background: Levodopa-Protein Interaction

The Challenge of Levodopa Bioavailability

Levodopa, the gold-standard treatment for Parkinson's disease, faces a fundamental pharmacological challenge: its journey from the gastrointestinal tract to the brain is compromised by competition with dietary amino acids.[@nutt1984]

When patients take levodopa with high-protein meals, the medication must compete with naturally occurring amino acids for absorption and brain entry. This competition occurs at two critical interfaces:

Clinical Impact

The protein-levodopa interaction has measurable clinical consequences:

• Reduced bioavailability — High-protein meals can decrease levodopa absorption by 30-50%
• Delayed onset — Peak plasma concentrations are delayed when levodopa is taken with protein-rich foods
• Variable response — Patients experience unpredictable "on/off" fluctuations related to meal timing
• Dosing complexity — Patients are often instructed to take levodopa 30-60 minutes before meals[@simon2010]

Large Neutral Amino Acid Transporters (LAT1)

Biology of LAT1

LAT1 (SLC7A5) is a heteromeric amino acid transporter that mediates the transport of large neutral amino acids across the blood-brain barrier. It operates as part of the system L transporter family, which handles:

• Essential amino acids: leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, histidine
• Non-essential amino acids: cysteine, glutamine, asparagine, serine
• Amino acid derivatives: levodopa, methyl-DOPA

LAT1 Structure and Function

LAT1 is a heterodimeric transporter composed of:

The transporter functions as a sodium-independent exchanger, using the concentration gradient of intracellular amino acids to drive uptake of extracellular substrates. At the blood-brain barrier, LAT1 is expressed on the luminal (blood-facing) and abluminal (brain-facing) membranes, facilitating bidirectional amino acid transport.[@del2008]

LAT1 in Neurodegeneration

LAT1 function is altered in several neurological conditions:

| Condition | LAT1 Alteration | Implications |
|-----------|-----------------|---------------|
| Parkinson's Disease | Competition with levodopa | Reduced medication efficacy |
| Alzheimer's Disease | Downregulation reported | Impaired amino acid delivery |
| Brain Tumors | Overexpression | Nutrient supply for tumors |
| Epilepsy | Dysregulation | Altered neurotransmitter precursors |

Amino Acid Metabolism in Parkinson's Disease

Altered Amino Acid Profiles in PD

Several studies have identified changes in amino acid metabolism in Parkinson's disease patients:[@cereda2013]

• Decreased plasma aromatic amino acids — Tyrosine and phenylalanine levels are reduced in PD patients compared to controls
• Elevated branched-chain amino acids — Some studies report increased BCAA levels
• Altered tryptophan metabolism — Changes in serotonin and kynurenine pathway metabolites
• Cysteine/glutathione alterations — Evidence of redox stress

Implications for Neurotransmitter Synthesis

Amino acids serve as precursors for neurotransmitters affected in Parkinson's disease:

Blood-Brain Barrier Transport Competition

The Transport Competition Model

When levodopa and dietary amino acids are present simultaneously in the bloodstream, they compete for LAT1-mediated transport into the brain. The kinetics of this competition follow basic principles:

• Km (Michaelis constant) — Each amino acid has a characteristic affinity for LAT1
• Vmax (maximum velocity) — The transport system has finite capacity
• Concentration gradient — Higher concentrations drive more transport[@jin2022]

Strategies to Overcome Competition

Several approaches have been investigated to improve levodopa delivery despite transport competition:

The NCT06954662 Approach

Clinical trial NCT06954662 evaluates a targeted amino acid supplement designed to optimize LAT1 function. The hypothesis is that:

• Strategic amino acid supplementation may enhance levodopa transport without interfering with its brain entry
• Specific amino acid ratios may favor levodopa over competing substrates
• The supplement may provide additional benefits through neurotransmitter precursor optimization

Mechanism of Action: Proposed Amino Acid Supplement Effects

Direct Transport Effects

The amino acid supplement in NCT06954662 is hypothesized to work through several mechanisms:

Neurochemical Effects

Beyond transport, amino acid supplementation may influence:

• Dopamine synthesis — Increased substrate (tyrosine) for dopamine production
• Neurotransmitter balance — Normalization of amino acid profiles
• Energy metabolism — BCAA as alternative brain fuel
• Redox protection — Cysteine for glutathione synthesis

Clinical Evidence

Historical Studies

Research on amino acid-levodopa interactions spans decades:

| Study | Finding |
|-------|---------|
| Nutt et al., 1984 | High-protein meals reduce levodopa bioavailability |
| Simon et al., 2010 | Protein redistribution improves motor fluctuations |
| Cereda et al., 2013 | Altered amino acid profiles in PD patients |
| Jin et al., 2022 | LAT1 expression changes in PD models |

Current Status of Amino Acid Supplementation

The evidence for targeted amino acid supplementation in PD remains evolving:

• Theoretical rationale — Strong mechanistic basis for transport competition
• Mixed clinical data — Some studies show benefit, others show minimal effect
• Safety profile — Generally well-tolerated, with amino acid supplementation being a recognized nutritional approach
• NCT06954662 — Aims to provide rigorous evidence for this approach

Safety Considerations

Potential Risks

Amino acid supplementation in PD patients may carry:

Contraindications

Patients with the following conditions may require careful evaluation:

• Renal insufficiency
• Hepatic dysfunction
• Phenylketonuria (for tyrosine-containing formulations)
• Known amino acid metabolism disorders

Significance for Parkinson's Disease Treatment

If NCT06954662 demonstrates efficacy, amino acid supplementation could represent:

Comparison with Other Approaches

| Approach | Mechanism | Advantages | Limitations |
|----------|-----------|------------|-------------|
| Amino Acid Supplement | Optimize transport | Non-pharmacological, low cost | Evidence still emerging |
| Protein Redistribution | Reduce competition | Established approach | Difficult to implement |
| Levodopa-Carbidopa Intestinal Gel | Continuous delivery | Effective for advanced PD | Invasive, expensive |
| COMT Inhibitors | Block metabolism | Enhance levodopa availability | Side effects |

• [Parkinson's Disease](/genes/ar)
• [Levodopa](/therapeutics/levodopa)
• [Blood-Brain Barrier Transport](/mechanisms/bbb-transport-mechanisms)
• [SLC7A5 (LAT1) Transporter](/genes/ran)
• [Dopamine Metabolism](/mechanisms/dopamine-metabolism)
• [Amino Acid Transporters](/genes/ran)
• [Parkinson's Disease Treatments](/genes/ar)

External Links

• [ClinicalTrials.gov - NCT06954662](https://clinicaltrials.gov/study/NCT06954662)
• [Parkinson's Foundation - Nutrition](https://www.parkinson.org/)
• [Michael J. Fox Foundation - PD Research](https://www.michaeljfox.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Amino Acid Supplement in Parkinson's Disease (NCT06954662) discovered through SciDEX knowledge graph analysis: